Abstract
A library with 63 paclitaxel analogues modified at the C10 position of paclitaxel has been prepared using parallel solution phase synthesis. Most of the C10 analogues were slightly less active than paclitaxel in the tubulin assembly assay and had reduced potency in the B16 melanoma and MCF-7 cell line cytotoxicity assays. These modifications at C10, however, did not lead to the total loss of activity, indicating that the C10 moiety of paclitaxel may not be directly involved in the drug-microtubule interactions, but could influence its binding affinity to P-glycoprotein. Approximately 50 percentof the analogues demonstrated better activity against the drug resistant cell line MCF7-ADR. However, the increase in activity was 10-fold at most. This result demonstrates that the cytotoxicity against this drug resistant cancer cell line is sensitive to structural changes at the C10 position of paclitaxel. It was also found that the presence of a nitrogen atom in the C10 substituent might play a role in the i nteraction of analogues with microtubules.
Keywords: Paclitaxel Analogues, taxus brevifolia, alzheimer disease, combinatorial chemistry, taxanes, tubulin assembly assay, cell cytotoxicity assay
Combinatorial Chemistry & High Throughput Screening
Title: A Systematic SAR Study of C10 Modified Paclitaxel Analogues Using a Combinatorial Approach
Volume: 5 Issue: 1
Author(s): Yanbin Liu, Syed M. Ali, Thomas C. Boge, Gunda I. Georg, Samuel Victory, Jan Zygmunt, Rebecca T. Marquez and Richard H. Himes
Affiliation:
Keywords: Paclitaxel Analogues, taxus brevifolia, alzheimer disease, combinatorial chemistry, taxanes, tubulin assembly assay, cell cytotoxicity assay
Abstract: A library with 63 paclitaxel analogues modified at the C10 position of paclitaxel has been prepared using parallel solution phase synthesis. Most of the C10 analogues were slightly less active than paclitaxel in the tubulin assembly assay and had reduced potency in the B16 melanoma and MCF-7 cell line cytotoxicity assays. These modifications at C10, however, did not lead to the total loss of activity, indicating that the C10 moiety of paclitaxel may not be directly involved in the drug-microtubule interactions, but could influence its binding affinity to P-glycoprotein. Approximately 50 percentof the analogues demonstrated better activity against the drug resistant cell line MCF7-ADR. However, the increase in activity was 10-fold at most. This result demonstrates that the cytotoxicity against this drug resistant cancer cell line is sensitive to structural changes at the C10 position of paclitaxel. It was also found that the presence of a nitrogen atom in the C10 substituent might play a role in the i nteraction of analogues with microtubules.
Export Options
About this article
Cite this article as:
Liu Yanbin, Ali M. Syed, Boge C. Thomas, Georg I. Gunda, Victory Samuel, Zygmunt Jan, Marquez T. Rebecca and Himes H. Richard, A Systematic SAR Study of C10 Modified Paclitaxel Analogues Using a Combinatorial Approach, Combinatorial Chemistry & High Throughput Screening 2002; 5 (1) . https://dx.doi.org/10.2174/1386207023330615
DOI https://dx.doi.org/10.2174/1386207023330615 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Pharmacokinetics, Organ Toxicity and Antitumor Activity of Docetaxel Loaded in Folate Targeted Cholesterol Based Micelles
Current Drug Delivery Photodynamic Therapy: The Light Treatment for Cutaneous Non- Melanoma Malignancies
Current Cancer Therapy Reviews The Role of STAT3 Signaling in Mediating Tumor Resistance to Cancer Therapy
Current Drug Targets Applications of Aptamers in Targeted Imaging: State of the Art
Current Topics in Medicinal Chemistry Non Polymeric Nanoparticles for Photodynamic Therapy Applications: Recent Developments
Current Medicinal Chemistry Statin Intolerance: Why and What to do – With a Focus on Diabetic People
Current Medicinal Chemistry Reprofiling of Troglitazone Towards More Active and Less Toxic Derivatives: A New Hope for Cancer Treatment?
Current Topics in Medicinal Chemistry Pseudogene PTENP1 Suppresses Gastric Cancer Progression by Modulating PTEN
Anti-Cancer Agents in Medicinal Chemistry Psychiatric Side Effects of Interferon Treatment
Current Drug Safety Advanced Methods for the Analysis of Testosterone
Current Medicinal Chemistry Novel VEGF-independent Strategies Targeting Tumor Vasculature: Clinical Aspects
Current Pharmaceutical Design Inducible Nitric Oxide Synthase-Vascular Endothelial Growth Factor Axis: A Potential Target to Inhibit Tumor Angiogenesis by Dietary Agents
Current Cancer Drug Targets Dietary Agents for Prostate Cancer Chemoprevention: An Overview
Current Cancer Therapy Reviews Estrogen Receptor Expression and its Relevant Signaling Pathway in Prostate Cancer: A Target of Therapy
Current Molecular Pharmacology Bowman-Birk Inhibitors from Legumes and Human Gastrointestinal Health: Current Status and Perspectives
Current Protein & Peptide Science Immunotherapy for Non-Small Cell Lung Cancer - Finally a Hint of Hope
Reviews on Recent Clinical Trials Renal Development: A Complex Process Dependent on Inductive Interaction
Current Pediatric Reviews Combination Therapies Using Metformin and/or Valproic Acid in Prostate Cancer: Possible Mechanistic Interactions
Current Cancer Drug Targets Dynamics of Toll-like Receptors Signaling in Skeletal Muscle Atrophy
Current Medicinal Chemistry Aromatase, Estrogens and Testicular Germ Cell Development
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)